2,100 sarcoma survivors join landmark study to uncover hidden Long-Term effects
NCT ID NCT06482957
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study follows 2,100 people of all ages who have had sarcoma, a rare cancer, to learn how the disease and its treatments affect them over time. Participants will fill out surveys, give blood, saliva, urine, stool, and tissue samples, and wear a FitBit to track activity. The goal is to better understand the long-term physical and emotional challenges survivors face, which could help improve future care and support.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2022
- Expected to finish
-
Apr 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients at any age with a history of sarcoma, with or without evidence of a persistent disease and parent/caregiver of pediatric patients and siblings of patients 8 years or older
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Patients at any age with a history of sarcoma, with or without evidence of a persistent disease • For pediatric patients * Parent/primary caregiver of patient * Sibling of patient aged 8 years or older
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Sarcoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Vanderbilt University/Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37203, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Blood-Flow-Blocking drug stall a rare sarcoma?
- Can a new drug shrink advanced solid tumors?
- Can a coordinated care team reduce severe side effects in older cancer patients?
- Can repeated MRI scans reveal how tumors respond to radiation?
- Can a new antibody help the immune system fight Hard-to-Treat tumors?
- Pedaling through chemo: could exercise boost tumor blood flow?